GlassScriptPhysician profile
L Steven Zukerman
NPI 1326015306
$41,266.00
in general payments reported to CMS, 2019-2025
15 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $60.93 · 2021: $6,515 · 2022: $9,620 · 2023: $7,959 · 2024: $5,147 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $1,270 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,864.00 |
| Food and Beverage | $1,270.23 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $33,993.77 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $6,226.38 | 2019-2025 | |
| Boston Scientific Corporation | $570.37 | 2019-2024 | Watchman Flx |
| Impulse Dynamics (USA) INC. | $156.39 | 2021-2022 | |
| Abbott Laboratories | $65.19 | 2025 | Aveir |
| Novartis Pharmaceuticals Corporation | $58.97 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.30 | 2025 | Lifevest |
| Heartflow, INC. | $37.63 | 2025 | |
| Medtronic Vascular, INC. | $36.78 | 2020 | |
| Amgen INC. | $16.93 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.67 | 2024 | Jardiance |
| Amarin Pharma, INC. | $14.80 | 2019 | |
| Novo Nordisk INC | $13.65 | 2024 | Wegovy |
| Janssen Pharmaceuticals, INC | $13.17 | 2024 | Xarelto |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw L Steven Zukerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.